A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
Zumutor Biologics Inc.
Sotio Biotech Inc.
SystImmune Inc.
Myeloid Therapeutics
NextCure, Inc.
Black Diamond Therapeutics, Inc.
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Taiho Pharmaceutical Co., Ltd.
Eli Lilly and Company
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Silverback Therapeutics
AstraZeneca
GlaxoSmithKline
Mannkind Corporation